

Pierre-Emmanuel Rautou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2187381/publications.pdf>

Version: 2024-02-01

146
papers

14,317
citations

38742

50
h-index

20358

116
g-index

154
all docs

154
docs citations

154
times ranked

24848
citing authors

#	ARTICLE	IF	CITATIONS
1	Liver surface nodularity on non-contrast MRI identifies advanced fibrosis in patients with NAFLD. <i>European Radiology</i> , 2022, 32, 1781-1791.	4.5	8
2	Multicenter study on recent portal venous system thrombosis associated with cytomegalovirus disease. <i>Journal of Hepatology</i> , 2022, 76, 115-122.	3.7	6
3	MR imaging features and long-term evolution of benign focal liver lesions in Budd-Chiari syndrome and Fontan-associated liver disease. <i>Diagnostic and Interventional Imaging</i> , 2022, 103, 111-120.	3.2	6
4	Role of Imaging in the Study of Vascular Disorders of the Liver. , 2022, , 15-33.		2
5	Pregnancy in Vascular Liver Disease. , 2022, , 237-248.		0
6	Role of Liver Biopsy in the Study of Vascular Disorders of the Liver. , 2022, , 3-13.		0
7	Performance of non-invasive biomarkers compared with invasive methods for risk prediction of posthepatectomy liver failure in hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2022, 109, 455-463.	0.3	7
8	Contrast-enhanced CT and liver surface nodularity for the diagnosis of porto-sinusoidal vascular disorder: A case-control study. <i>Hepatology</i> , 2022, 76, 418-428.	7.3	11
9	EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. <i>Journal of Hepatology</i> , 2022, 76, 1151-1184.	3.7	112
10	Reply. <i>Hepatology</i> , 2022, 76, E55-E56.	7.3	0
11	Imaging-guided interventions modulating portal venous flow: evidence and controversies. <i>JHEP Reports</i> , 2022, , 100484.	4.9	1
12	Impact of SARS-CoV-2 Pandemic on Vascular Liver Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1525-1533.e5.	4.4	9
13	Portal vein recanalisation alone to treat severe portal hypertension in non-cirrhotic patients with chronic extrahepatic portal vein obstruction. <i>JHEP Reports</i> , 2022, 4, 100511.	4.9	10
14	Elastography improves accuracy of early hepato-biliary complications diagnosis after allogeneic stem cell transplantation. <i>Haematologica</i> , 2021, 106, 2374-2383.	3.5	14
15	Benefits of molecular profiling with next-generation sequencing for the diagnosis and prognosis of myeloproliferative neoplasms in splanchnic vein thrombosis. <i>Journal of Hepatology</i> , 2021, 74, 251-252.	3.7	5
16	Computed Tomography-Derived Liver Surface Nodularity and Sarcopenia as Prognostic Factors in Patients with Resectable Metabolic Syndrome-Related Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 405-416.	1.5	10
17	Liver Stiffness by Transient Elastography to Detect Porto-sinusoidal Vascular Liver Disease With Portal Hypertension. <i>Hepatology</i> , 2021, 74, 364-378.	7.3	40
18	Patients with NAFLD do not have severe portal hypertension in the absence of cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1269-1270.	3.7	7

#	ARTICLE	IF	CITATIONS
19	Venous thrombosis and predictors of relapse in eosinophil-related diseases. <i>Scientific Reports</i> , 2021, 11, 6388.	3.3	18
20	Endothelial dysfunction markers predict short-term mortality in patients with severe alcoholic hepatitis. <i>Hepatology International</i> , 2021, 15, 1006-1017.	4.2	6
21	REPLY:. <i>Hepatology</i> , 2021, 74, 2317-2318.	7.3	0
22	REPLY:. <i>Hepatology</i> , 2021, 74, 2911-2912.	7.3	0
23	Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. <i>Journal of Hepatology</i> , 2021, 75, 1026-1033.	3.7	59
24	NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF VASCULAR LIVER DISEASES. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 46, 101764.	1.5	1
25	Role of extracellular vesicles in liver diseases and their therapeutic potential. <i>Advanced Drug Delivery Reviews</i> , 2021, 175, 113816.	13.7	37
26	Systemic inflammation as a risk factor for portal vein thrombosis in cirrhosis: a prospective longitudinal study. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e108-e113.	1.6	16
27	Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation. <i>Journal of Hepatology</i> , 2020, 72, 463-471.	3.7	38
28	Prevalence, features and predictive factors of liver nodules in Fontan surgery patients: The VALDIG Fonliver prospective cohort. <i>Journal of Hepatology</i> , 2020, 72, 702-710.	3.7	45
29	A defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis. <i>Journal of Hepatology</i> , 2020, 72, 528-538.	3.7	113
30	Quantification of hepatic steatosis with ultrasound: promising role of attenuation imaging coefficient in a biopsy-proven cohort. <i>European Radiology</i> , 2020, 30, 2293-2301.	4.5	65
31	Performance of liver surface nodularity quantification for the diagnosis of portal hypertension in patients with cirrhosis: comparison between MRI with hepatobiliary phase sequences and CT. <i>Abdominal Radiology</i> , 2020, 45, 365-372.	2.1	16
32	Extracellular vesicles as biomarkers in liver diseases: A clinician's point of view. <i>Journal of Hepatology</i> , 2020, 73, 1507-1525.	3.7	105
33	Similar performance of liver stiffness measurement and liver surface nodularity for the detection of portal hypertension in patients with hepatocellular carcinoma. <i>JHEP Reports</i> , 2020, 2, 100147.	4.9	15
34	Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. <i>Blood Advances</i> , 2020, 4, 3708-3715.	5.2	31
35	Interaction between the autophagy protein Beclin 1 and Na ⁺ ,K ⁺ -ATPase during starvation, exercise, and ischemia. <i>JCI Insight</i> , 2020, 5, .	5.0	37
36	No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease. <i>Journal of Hepatology</i> , 2020, 73, 717-718.	3.7	42

#	ARTICLE	IF	CITATIONS
37	Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome. <i>JHEP Reports</i> , 2020, 2, 100097.	4.9	11
38	2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: An individual patient data meta-analysis. <i>Liver International</i> , 2020, 40, 1435-1446.	3.9	35
39	Porto-sinusoidal vascular disease. Vascular liver diseases: Position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFLF), and ERN-rare liver. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 447-451.	1.5	5
40	Characterization of Blood Immune Cells in Patients With Decompensated Cirrhosis Including ACLF. <i>Frontiers in Immunology</i> , 2020, 11, 619039.	4.8	39
41	Ischemic cholangiopathy: An update. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 486-490.	1.5	7
42	Microcirculatory changes in the liver of patients with refractory ascites and their relationship with diabetes and alcohol. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, .	1.6	2
43	Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm. <i>Journal of Clinical Investigation</i> , 2020, 130, 2630-2643.	8.2	42
44	Liver Disease; Hemostasis and Coagulation Disorders. , 2020, , 418-428.		0
45	Angioplasty with stenting for Budd-Chiari syndrome. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 657-659.	8.1	3
46	Autophagy in liver diseases: Time for translation?. <i>Journal of Hepatology</i> , 2019, 70, 985-998.	3.7	252
47	Nonselective beta-blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 582-588.	3.7	48
48	Comparison of endothelial promoter efficiency and specificity in mice reveals a subset of Pdgfr-positive hematopoietic cells. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 827-840.	3.8	24
49	Abdominal Surgery in Patients With Idiopathic Noncirrhotic Portal Hypertension: A Multicenter Retrospective Study. <i>Hepatology</i> , 2019, 70, 911-924.	7.3	11
50	Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease. <i>American Journal of Pathology</i> , 2019, 189, 1159-1175.	3.8	19
51	Porto-sinusoidal vascular disease: proposal and description of a novel entity. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 399-411.	8.1	149
52	Short- and Long-Term Outcomes of Liver Resection for Intrahepatic Cholangiocarcinoma Associated with the Metabolic Syndrome. <i>World Journal of Surgery</i> , 2019, 43, 2048-2060.	1.6	17
53	Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 70, 1278-1291.	3.7	186
54	Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis. <i>Journal of Hepatology</i> , 2019, 71, 175-199.	3.7	80

#	ARTICLE	IF	CITATIONS
55	Reply to: "Splenic artery aneurysms, portal hypertension and pregnancy" Journal of Hepatology, 2019, 70, 1026-1027.	3.7	2
56	Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with Budd-Chiari syndrome. Journal of Hepatology, 2019, 70, 1123-1132.	3.7	37
57	Evidence for an Association Between Intrahepatic Vascular Changes and the Development of Hepatopulmonary Syndrome. Chest, 2019, 155, 123-136.	0.8	21
58	Primary cilia sensitize endothelial cells to BMP and prevent excessive vascular regression. Journal of Cell Biology, 2018, 217, 1651-1665.	5.2	84
59	Endothelial Autophagy Does Not Influence Venous Thrombosis in Mice. Thrombosis and Haemostasis, 2018, 118, 1113-1115.	3.4	3
60	Benign and malignant hepatocellular lesions in patients with vascular liver diseases. Abdominal Radiology, 2018, 43, 1968-1977.	2.1	44
61	Endothelial JAK2 does not enhance liver lesions in mice with Budd-Chiari syndrome. Journal of Hepatology, 2018, 68, 1086-1087.	3.7	3
62	Diagnosis of Budd-Chiari syndrome. Abdominal Radiology, 2018, 43, 1896-1907.	2.1	35
63	Non-invasive evaluation of portal hypertension using shear-wave elastography: analysis of two algorithms combining liver and spleen stiffness in 191 patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2018, 47, 621-630.	3.7	46
64	Bleeding risk of variceal band ligation in extrahepatic portal vein obstruction is not increased by oral anticoagulation. European Journal of Gastroenterology and Hepatology, 2018, 30, 563-568.	1.6	17
65	Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis. Hepatology, 2018, 68, 1508-1518.	7.3	33
66	NADPH oxidase depletion in neutrophils from patients with cirrhosis and restoration via toll-like receptor 7/8 activation. Gut, 2018, 67, 1505-1516.	12.1	29
67	Endothelial autophagic flux hampers atherosclerotic lesion development. Autophagy, 2018, 14, 173-175.	9.1	24
68	Ultra-short bowel is an independent risk factor for liver fibrosis in adults with home parenteral nutrition. Liver International, 2018, 38, 174-182.	3.9	30
69	Ultrasonic fat fraction quantification using <i>in vivo</i> adaptive sound speed estimation. Physics in Medicine and Biology, 2018, 63, 215013.	3.0	38
70	Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis. Gastroenterology, 2018, 155, 1816-1827.e9.	1.3	113
71	Quantification of Liver Surface Nodularity at CT: Utility for Detection of Portal Hypertension. Radiology, 2018, 289, 698-707.	7.3	45
72	Cirrhosis regression: extrahepatic angiogenesis and liver hyperarterialization persist. Clinical Science, 2018, 132, 1341-1343.	4.3	4

#	ARTICLE	IF	CITATIONS
73	Pregnancy in idiopathic non-cirrhotic portal hypertension: A multicentric study on maternal and fetal management and outcome. <i>Journal of Hepatology</i> , 2018, 69, 1242-1249.	3.7	26
74	Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver. <i>Nature Communications</i> , 2018, 9, 2146.	12.8	152
75	Type I interferon signaling in systemic immune cells from patients with alcoholic cirrhosis and its association with outcome. <i>Journal of Hepatology</i> , 2017, 66, 930-941.	3.7	26
76	Extracellular vesicles in coronary artery disease. <i>Nature Reviews Cardiology</i> , 2017, 14, 259-272.	13.7	392
77	A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis. <i>Hepatology</i> , 2017, 66, 555-563.	7.3	91
78	Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. <i>Journal of Hepatology</i> , 2017, 67, 501-507.	3.7	50
79	Iloprost Use in Patients with Persistent Intestinal Ischemia Unsuitable for Revascularization. <i>Annals of Vascular Surgery</i> , 2017, 42, 128-135.	0.9	6
80	Autophagy is required for endothelial cell alignment and atheroprotection under physiological blood flow. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E8675-E8684.	7.1	156
81	Quantitative Imaging in Diffuse Liver Diseases. <i>Seminars in Liver Disease</i> , 2017, 37, 243-258.	3.6	11
82	Pre-therapy liver transcriptome landscape in Indian and French patients with severe alcoholic hepatitis and steroid responsiveness. <i>Scientific Reports</i> , 2017, 7, 6816.	3.3	16
83	Idiopathic Non-cirrhotic Portal Hypertension and Close Entities: a Need for Clarifying Terminology. <i>Current Hepatology Reports</i> , 2017, 16, 237-240.	0.9	0
84	Reply to: "Calreticulin mutations and their importance in Budd-Chiari syndrome". <i>Journal of Hepatology</i> , 2017, 67, 1112-1113.	3.7	0
85	Long-term Outcome and Analysis of Dysfunction of Transjugular Intrahepatic Portosystemic Shunt Placement in Chronic Primary Budd-Chiari Syndrome. <i>Radiology</i> , 2017, 283, 280-292.	7.3	54
86	Liver sinusoidal endothelial cells: Physiology and role in liver diseases. <i>Journal of Hepatology</i> , 2017, 66, 212-227.	3.7	639
87	Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension. <i>Hepatology</i> , 2016, 64, 224-231.	7.3	69
88	Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. <i>Hepatology</i> , 2016, 63, 1640-1650.	7.3	73
89	Arterial hypertension as an uninvited player in hepatic stiffness?. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, G942-G944.	3.4	3
90	LPS-TLR4 Pathway Mediates Ductular Cell Expansion in Alcoholic Hepatitis. <i>Scientific Reports</i> , 2016, 6, 35610.	3.3	25

#	ARTICLE	IF	CITATIONS
91	Diabetes mellitus in patients with cirrhosis: clinical implications and management. <i>Liver International</i> , 2016, 36, 936-948.	3.9	139
92	Idiopathic non- α -cirrhotic portal hypertension: the tip of the obliterative portal venopathies iceberg?. <i>Liver International</i> , 2016, 36, 325-327.	3.9	11
93	Lack of clinical or haemodynamic rebound after abrupt interruption of beta-blockers in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 966-973.	3.7	11
94	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
95	Hepatocyte tissue factor contributes to the hypercoagulable state in a mouse model of chronic liver injury. <i>Journal of Hepatology</i> , 2016, 64, 53-59.	3.7	36
96	Acute extrahepatic infectious or inflammatory diseases are a cause of transient mosaic pattern on CT and MR imaging related to sinusoidal dilatation of the liver. <i>European Radiology</i> , 2016, 26, 3094-3101.	4.5	19
97	Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPAR α expression. <i>Gut</i> , 2016, 65, 1882-1894.	12.1	140
98	The significance of nonobstructive sinusoidal dilatation of the liver: Impaired portal perfusion or inflammatory reaction syndrome. <i>Hepatology</i> , 2015, 62, 956-963.	7.3	54
99	Autosis occurs in the liver of patients with severe anorexia nervosa. <i>Hepatology</i> , 2015, 62, 657-658.	7.3	35
100	Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles. <i>Hepatology</i> , 2015, 61, 1041-1055.	7.3	102
101	Pregnancy and Vascular Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2015, 5, 41-50.	0.9	42
102	Interplay of Inflammation and Endothelial Dysfunction in Bone Marrow Transplantation: Focus on Hepatic Venous Occlusive Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 629-643.	2.7	48
103	Resolution of liver fibrosis requires myeloid cell-driven sinusoidal angiogenesis. <i>Hepatology</i> , 2015, 61, 2042-2055.	7.3	79
104	Prospective Comparison of Spleen and Liver Stiffness by Using Shear-Wave and Transient Elastography for Detection of Portal Hypertension in Cirrhosis. <i>Radiology</i> , 2015, 275, 589-598.	7.3	190
105	Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: Results of a longitudinal study. <i>Hepatology</i> , 2015, 61, 660-667.	7.3	364
106	Liver Autophagy in Anorexia Nervosa and Acute Liver Injury. <i>BioMed Research International</i> , 2014, 2014, 1-10.	1.9	44
107	Circulating microparticle tissue factor activity is increased in patients with cirrhosis. <i>Hepatology</i> , 2014, 60, 1793-1795.	7.3	31
108	Managing periprocedural thrombocytopenia in cirrhosis: Aiming for a safety window. <i>Journal of Hepatology</i> , 2014, 61, 1199-1201.	3.7	2

#	ARTICLE	IF	CITATIONS
109	Budd-Chiari syndrome. <i>Clinical Liver Disease</i> , 2014, 3, 133-136.	2.1	2
110	Benign and malignant hepatocellular lesions in patients with vascular liver disease. <i>Clinical Liver Disease</i> , 2014, 3, 122-125.	2.1	3
111	The emerging roles of microvesicles in liver diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 350-361.	17.8	158
112	Assessment of portal hypertension and high-risk oesophageal varices with liver and spleen three-dimensional multifrequency MR elastography in liver cirrhosis. <i>European Radiology</i> , 2014, 24, 1394-402.	4.5	103
113	Inhibition of MicroRNA-92a Prevents Endothelial Dysfunction and Atherosclerosis in Mice. <i>Circulation Research</i> , 2014, 114, 434-443.	4.5	317
114	Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. <i>Hepatology</i> , 2014, 60, 823-831.	7.3	135
115	Type 2 diabetes mellitus as a risk factor for intestinal resection in patients with superior mesenteric vein thrombosis. <i>Liver International</i> , 2014, 34, 1314-1321.	3.9	48
116	Editorial: G-CSF Therapy for Severe Alcoholic Hepatitis: Targeting Liver Regeneration or Neutrophil Function?. <i>American Journal of Gastroenterology</i> , 2014, 109, 1424-1426.	0.4	29
117	Gene- and exon-expression profiling reveals an extensive LPS-induced response in immune cells in patients with cirrhosis. <i>Journal of Hepatology</i> , 2013, 58, 936-948.	3.7	66
118	Circulating platelet derived microparticles are not increased in patients with cirrhosis. <i>Journal of Hepatology</i> , 2013, 59, 912.	3.7	7
119	Microvesicles as risk markers for venous thrombosis. <i>Expert Review of Hematology</i> , 2013, 6, 91-101.	2.2	51
120	Management of hepatic vascular diseases. <i>Journal of Hepatology</i> , 2012, 56, S25-S38.	3.7	167
121	Endothelial Cell-derived Microparticles Loaded with Iron Oxide Nanoparticles: Feasibility of MR Imaging Monitoring in Mice. <i>Radiology</i> , 2012, 263, 169-178.	7.3	38
122	Severe hyponatremia is a better predictor of mortality than MELDNa in patients with cirrhosis and refractory ascites. <i>Journal of Hepatology</i> , 2012, 57, 274-280.	3.7	67
123	Abnormal Plasma Microparticles Impair Vasoconstrictor Responses in Patients With Cirrhosis. <i>Gastroenterology</i> , 2012, 143, 166-176.e6.	1.3	105
124	Endothelial progenitor cells in cirrhosis: The more, the merrier?. <i>Journal of Hepatology</i> , 2012, 57, 1163-1165.	3.7	8
125	Deletion of Microvesicles From the Circulation. <i>Circulation</i> , 2012, 125, 1601-1604.	1.6	22
126	Changes in Autophagic Response in Patients with Chronic Hepatitis C Virus Infection. <i>American Journal of Pathology</i> , 2011, 178, 2708-2715.	3.8	58

#	ARTICLE	IF	CITATIONS
127	Predictors of tumor response after preoperative chemoradiotherapy for rectal adenocarcinomas. <i>Human Pathology</i> , 2011, 42, 1702-1709.	2.0	28
128	Bleeding in patients with Budd-Chiari syndrome. <i>Journal of Hepatology</i> , 2011, 54, 56-63.	3.7	61
129	Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: A cross-over study. <i>Journal of Hepatology</i> , 2011, 55, 794-799.	3.7	177
130	Microparticles, Vascular Function, and Atherothrombosis. <i>Circulation Research</i> , 2011, 109, 593-606.	4.5	331
131	Microparticles From Human Atherosclerotic Plaques Promote Endothelial ICAM-1-Dependent Monocyte Adhesion and Transendothelial Migration. <i>Circulation Research</i> , 2011, 108, 335-343.	4.5	221
132	Syndrôme de Budd-Chiari primitif. <i>Sang Thrombose Vaisseaux</i> , 2010, 22, 201-208.	0.1	1
133	Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. <i>Hepatology</i> , 2010, 52, 1017-1022.	7.3	452
134	The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. <i>Liver International</i> , 2010, 30, 725-732.	3.9	149
135	Magnetic tagging of cell-derived microparticles: new prospects for imaging and manipulation of these mediators of biological information. <i>Nanomedicine</i> , 2010, 5, 727-738.	3.3	18
136	Microparticles: Key Protagonists in Cardiovascular Disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 907-916.	2.7	127
137	Dysphagia in a Patient With Recurrent Bilateral Eyelid Ptosis. <i>Gastroenterology</i> , 2010, 139, 1835-2226.	1.3	0
138	Autophagy in liver diseases. <i>Journal of Hepatology</i> , 2010, 53, 1123-1134.	3.7	351
139	Prognostic Indices for Budd-Chiari Syndrome: Valid for Clinical Studies but Insufficient for Individual Management. <i>American Journal of Gastroenterology</i> , 2009, 104, 1140-1146.	0.4	65
140	Pregnancy in women with known and treated Budd-Chiari syndrome: Maternal and fetal outcomes. <i>Journal of Hepatology</i> , 2009, 51, 47-54.	3.7	85
141	Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas. <i>Journal of Hepatology</i> , 2009, 51, 93-101.	3.7	83
142	Levels and Initial Course of Serum Alanine Aminotransferase Can Predict Outcome of Patients With Budd-Chiari Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1230-1235.	4.4	39
143	Acute Liver Cell Damage in Patients With Anorexia Nervosa: A Possible Role of Starvation-Induced Hepatocyte Autophagy. <i>Gastroenterology</i> , 2008, 135, 840-848.e3.	1.3	165
144	CD40 Ligand+ Microparticles From Human Atherosclerotic Plaques Stimulate Endothelial Proliferation and Angiogenesis. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1302-1311.	2.8	176

#	ARTICLE	IF	CITATIONS
145	Morphologic Changes in Branch Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Midterm Follow-Up Study. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 807-814.	4.4	117
146	Hepatitis C virus eradication followed by HBeAg to anti-HBe seroconversion after pegylated interferon-??2b plus ribavirin treatment in a patient with hepatitis B and C coinfection. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 1019-1022.	1.6	16